135 related articles for article (PubMed ID: 38714521)
1. Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells.
Choi SY; Kim Y; Lim B; Wee CB; Chang IH; Kim CS
Investig Clin Urol; 2024 May; 65(3):300-310. PubMed ID: 38714521
[TBL] [Abstract][Full Text] [Related]
2. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
3. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
4. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
5. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
[TBL] [Abstract][Full Text] [Related]
6. Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by
Versteven M; Flumens D; Campillo-Davó D; De Reu H; Van Bruggen L; Peeters S; Van Tendeloo V; Berneman Z; Dolstra H; Anguille S; Hobo W; Smits E; Lion E
Front Immunol; 2022; 13():734256. PubMed ID: 35250967
[TBL] [Abstract][Full Text] [Related]
7. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
8. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
Hobo W; Maas F; Adisty N; de Witte T; Schaap N; van der Voort R; Dolstra H
Blood; 2010 Nov; 116(22):4501-11. PubMed ID: 20682852
[TBL] [Abstract][Full Text] [Related]
9. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
10. Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ.
Švajger U; Tešić N; Rožman P
Int Immunopharmacol; 2021 Oct; 99():107978. PubMed ID: 34298399
[TBL] [Abstract][Full Text] [Related]
11. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Hayakawa T; Yaguchi T; Kawakami Y
Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
[TBL] [Abstract][Full Text] [Related]
12. Dendritic Cells Exposed to Triiodothyronine Deliver Pro-Inflammatory Signals and Amplify IL-17-Driven Immune Responses.
Alamino VA; Montesinos MDM; Soler MF; Giusiano L; Gigena N; Fozzatti L; Maller SM; Méndez-Huergo SP; Rabinovich GA; Pellizas CG
Cell Physiol Biochem; 2019; 52(2):354-367. PubMed ID: 30816679
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
14. [Effect of PD-L1 blockade on function of dendritic cells derived from chronic myelocytic leukemia].
Wang CY; Zhang LS; Tian FQ; Huang R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1146-9. PubMed ID: 18928614
[TBL] [Abstract][Full Text] [Related]
15. Blockade of B7-H1 enhances dendritic cell-mediated T cell response and antiviral immunity in HBV transgenic mice.
Jiang W
Vaccine; 2012 Jan; 30(4):758-66. PubMed ID: 22133510
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells induce specific cytotoxic T lymphocytes against prostate cancer TRAMP-C2 cells loaded with freeze- thaw antigen and PEP-3 peptide.
Liu XQ; Jiang R; Li SQ; Wang J; Yi FP
Asian Pac J Cancer Prev; 2015; 16(2):571-8. PubMed ID: 25684489
[TBL] [Abstract][Full Text] [Related]
17. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
Krempski J; Karyampudi L; Behrens MD; Erskine CL; Hartmann L; Dong H; Goode EL; Kalli KR; Knutson KL
J Immunol; 2011 Jun; 186(12):6905-13. PubMed ID: 21551365
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
Bishop JL; Sio A; Angeles A; Roberts ME; Azad AA; Chi KN; Zoubeidi A
Oncotarget; 2015 Jan; 6(1):234-42. PubMed ID: 25428917
[TBL] [Abstract][Full Text] [Related]
20. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
